The Medicines Patent Pool Announces First Licence for Tuberculosis Treatment

In an effort to improve the international response to combatting multidrug-resistant TB, MPP and Johns Hopkins University sign licensing agreement for investigational treatment sutezolid   Geneva, 25 January 2017  — The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical … Read more

Sandoz and Beximco Pharmaceuticals Join the Medicines Patent Pool’s Growing Network of Generic Manufacturing Partners

On World AIDS Day, the organisation releases new impact numbers noting progress of generic partners to deliver low-cost, high quality HIV medicines to developing countries Geneva, 1 December 2016  — The Medicines Patent Pool (MPP) today announced the expansion of its network of generic manufacturers to include Sandoz and Beximco … Read more

[MPP Statement] Access to Medicine Index 2016 Published Today with High Marks for Companies that License to the Medicines Patent Pool (MPP)

Biennial ‘Report Card’ also notes that the MPP has been central driver of access-oriented licensing in the pharmaceutical industry (GENEVA, November 14, 2016) – The Access to Medicine (ATM) Index issued its biennial report today giving high marks to companies that have negotiated licences for antiretrovirals and hepatitis C medicines … Read more

The Medicines Patent Pool Announces First World Health Organization Prequalification Submissions for Generic Dolutegravir

Cipla and Mylan are the first companies to apply for WHO’s prequalification of dolutegravir   Geneva, 10 November 2016  — The Medicines Patent Pool (MPP) announced today that two of its generic manufacturing partners are the first companies to apply for prequalification of generic dolutegravir (DTG), a new antiretroviral that … Read more

[MPP Statement] Lancet Commission Report on Essential Medicines for Universal Health Coverage: Identifies Positive Role of Patent Pooling and Voluntary Licensing

Geneva, 08 November 2016 —The Medicines Patent Pool welcomes the report published today by the Lancet Commission on Essential Medicines Policies and its recognition that the MPP model, or a similar approach, could support the international public health commitment to access to essential medicines. The Lancet Commission, a group of … Read more

The Medicines Patent Pool Expands its Expert Advisory Group (EAG) to Include Leaders with Expertise in Hepatitis C and Tuberculosis

Geneva, 10 October 2016 —The MPP announced the expansion of its Expert Advisory Group (EAG), an independent group of advisors providing counsel on licensing agreements, to include eleven new members with hepatitis C and tuberculosis expertise. The newly constituted EAG will now operate in three subgroups focusing on one of … Read more

The Medicines Patent Pool Announces MedsPaL: Its New Medicines Patents & Licences Database

MPP’s signature database upgraded to include patent and licensing data for HIV, hepatitis C and tuberculosis medicines Geneva, 5 October 2016 – The Medicines Patent Pool today announced the launch of MedsPaL, its Medicines Patents & Licences Database, a new resource for information on the intellectual property status of priority … Read more

The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments

Zydus Cadila joins the MPP as new partner Geneva, 07 July 2016 – The Medicines Patent Pool (MPP) announced new generic manufacturing licences today for four antiretrovirals and hepatitis C direct-acting antiviral daclatasvir. The organisation signed licences with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner Zydus … Read more

The Medicines Patent Pool Releases 2015 Annual Report: Five Years of Patent Pooling for Public Health

MPP Reports $195 Million in Savings through Partners’ Supply of Low-Cost Medicines (GENEVA, 26 May 2016) — The Medicines Patent Pool (MPP) released its 2015 Annual Report today reviewing last year’s accomplishments and highlighting its half decade of work in public health-oriented voluntary licensing to improve access to HIV medicines … Read more

ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to all Lower Middle-Income Countries

Specifically benefits more than 270,000 people living with HIV in Armenia, Moldova, Morocco and Ukraine   Geneva, 25 April 2016 — The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover … Read more